CC BY 4.0 · Thromb Haemost
DOI: 10.1055/a-2464-2887
Siraj Mithoowani
1
Department of Medicine, McMaster University, Hamilton, Canada
,
Tammy Bungard
2
Department of Medicine, University of Alberta, Edmonton, Canada
,
Lana Castellucci
3
Department of Medicine, University of Ottawa, Ottawa, Canada
4
Inflammation and Chronic Disease Program, Ottawa Hospital Research Institute, Ottawa, Canada
,
Mark Crowther
1
Department of Medicine, McMaster University, Hamilton, Canada
,
Kerstin de Wit
5
Department of Emergency Medicine, Queen's University, Kingston, Canada
,
Dar Dowlatshahi
3
Department of Medicine, University of Ottawa, Ottawa, Canada
4
Inflammation and Chronic Disease Program, Ottawa Hospital Research Institute, Ottawa, Canada
,
Nauzer Forbes
6
Department of Medicine, University of Calgary, Calgary, Canada
,
Katie Lin
6
Department of Medicine, University of Calgary, Calgary, Canada
,
Deborah M. Siegal
3
Department of Medicine, University of Ottawa, Ottawa, Canada
4
Inflammation and Chronic Disease Program, Ottawa Hospital Research Institute, Ottawa, Canada
› Author Affiliations
Funding Thrombosis Canada received an unrestricted educational grant from AstraZeneca to develop this algorithm. The funding source had no role in the design, content, writing, editing, or decision to submit this manuscript for publication.
› Further Information
Also available at
![SFX Search]()
Permissions and Reprints
Abstract
Bleeding complications associated with oral anticoagulant (OAC) frequently lead to emergency department visits and hospitalization. Short-term all-cause mortality after severe bleeding is substantial ranging from approximately 10% for gastrointestinal bleeding (the most frequent single site) to approximately 50% for intracranial bleeding. A protocol for multidisciplinary approach to bleeding is needed to (i) ensure rapid identification of patients at risk of adverse outcomes, (ii) optimize delivery of supportive measures, (iii) treat the source of bleeding, and (iv) administer anticoagulant reversal or hemostatic therapies judiciously for patients most likely to benefit. We convened a multidisciplinary panel of experts (emergency medicine, gastroenterology, general internal medicine, hematology, neurology, pharmacy, thrombosis) to review the literature and provide practical guidance including a corresponding algorithm for use at the point of care to assist clinicians in the management of patients with acute severe OAC-related bleeding.
Keywords
anticoagulation -
bleeding -
anticoagulant reversal -
warfarin -
DOAC -
treatment
Publication History
Received: 25 July 2024
Accepted: 05 November 2024
Accepted Manuscript online:
08 November 2024
Article published online:
13 December 2024
© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
References
1
Weitz JI,
Semchuk W,
Turpie AG.
et al.
Trends in prescribing oral anticoagulants in Canada, 2008–2014. Clin Ther 2015; 37 (11) 2506-2514.e4
2
Kirley K,
Qato DM,
Kornfield R,
Stafford RS,
Alexander GC.
National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes 2012; 5 (05) 615-621
3
Ohlrogge AH,
Brederecke J,
Schnabel RB.
Global burden of atrial fibrillation and flutter by national income: results from the Global Burden of Disease 2019 database. J Am Heart Assoc 2023; 12 (17) e030438
4 Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154 (13) 1449-1457
5
Heit JA.
Epidemiology of venous thromboembolism. Nat Rev Cardiol 2015; 12 (08) 464-474
6
Budnitz DS,
Lovegrove MC,
Shehab N,
Richards CL.
Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011; 365 (21) 2002-2012
7
Bayoumi I,
Dolovich L,
Hutchison B,
Holbrook A.
Medication-related emergency department visits and hospitalizations among older adults. Can Fam Physician 2014; 60 (04) e217-e222
8
Ruff CT,
Giugliano RP,
Braunwald E.
et al.
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383 (9921) 955-962
9
Kirchhof P,
Benussi S,
Kotecha D.
et al;
ESC Scientific Document Group.
2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37 (38) 2893-2962
10
Ferrazzini E,
Méan M,
Stalder O,
Limacher A,
Rodondi N,
Aujesky D.
Incidence and clinical impact of bleeding events in older patients with acute venous thromboembolism. Blood Adv 2023; 7 (02) 205-213
11
Hlavacek P,
Guo JD,
Rosenblatt L.
et al.
Safety, effectiveness, and health care cost comparisons among elderly patients with venous thromboembolism prescribed warfarin or apixaban in the United States Medicare population. Curr Med Res Opin 2019; 35 (12) 2043-2051
12
Linkins LA,
Choi PT,
Douketis JD.
Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 2003; 139 (11) 893-900
13
Aryal MR,
Gosain R,
Donato A.
et al.
Systematic review and meta-analysis of the efficacy and safety of apixaban compared to rivaroxaban in acute VTE in the real world. Blood Adv 2019; 3 (15) 2381-2387
14
Sindet-Pedersen C,
Staerk L,
Pallisgaard JL.
et al.
Safety and effectiveness of rivaroxaban and apixaban in patients with venous thromboembolism: a nationwide study. Eur Heart J Cardiovasc Pharmacother 2018; 4 (04) 220-227
15
Catella J,
Bertoletti L,
Moustafa F.
et al;
RIETE Investigators.
Major gastrointestinal bleeding in patients receiving anticoagulant therapy for venous thromboembolism. Thromb Res 2022; 214: 29-36
16
Dawwas GK,
Leonard CE,
Lewis JD,
Cuker A.
Risk for recurrent venous thromboembolism and bleeding with apixaban compared with rivaroxaban: an analysis of real-world data. Ann Intern Med 2022; 175 (01) 20-28
17
Schulman S,
Kakkar AK,
Goldhaber SZ.
et al;
RE-COVER II Trial Investigators.
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014; 129 (07) 764-772
18
Schulman S,
Kearon C,
Kakkar AK.
et al;
RE-MEDY Trial Investigators,
RE-SONATE Trial Investigators.
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013; 368 (08) 709-718
19
Büller HR,
Décousus H,
Grosso MA.
et al;
Hokusai-VTE Investigators.
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369 (15) 1406-1415
20
Prins MH,
Lensing AW,
Bauersachs R.
et al;
EINSTEIN Investigators.
Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 2013; 11 (01) 21
21
Raskob G,
Büller H,
Prins M.
et al;
Hokusai-VTE Investigators.
Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study—methodological implications for clinical trials. J Thromb Haemost 2013; 11 (07) 1287-1294
22
Wells PS,
Prins MH,
Levitan B.
et al.
Long-term anticoagulation with rivaroxaban for preventing recurrent VTE: a benefit-risk analysis of EINSTEIN-Extension. Chest 2016; 150 (05) 1059-1068
23
Agnelli G,
Becattini C,
Meyer G.
et al;
Caravaggio Investigators.
Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020; 382 (17) 1599-1607
24
Agnelli G,
Buller HR,
Cohen A.
et al;
AMPLIFY Investigators.
Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369 (09) 799-808
25
Agnelli G,
Buller HR,
Cohen A.
et al;
AMPLIFY-EXT Investigators.
Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368 (08) 699-708
26
Young AM,
Marshall A,
Thirlwall J.
et al.
Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018; 36 (20) 2017-2023
27
Bahit MC,
Lopes RD,
Wojdyla DM.
et al.
Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation. Heart 2017; 103 (08) 623-628
28
Patel MR,
Mahaffey KW,
Garg J.
et al;
ROCKET AF Investigators.
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365 (10) 883-891
29
Giugliano RP,
Ruff CT,
Braunwald E.
et al;
ENGAGE AF-TIMI 48 Investigators.
Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369 (22) 2093-2104
30
Connolly SJ,
Crowther M,
Eikelboom JW.
et al;
ANNEXA-4 Investigators.
Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med 2019; 380 (14) 1326-1335
31
Pollack Jr CV,
Reilly PA,
Weitz JI.
Dabigatran reversal with idarucizumab. N Engl J Med 2017; 377 (17) 1691-1692
32
Held C,
Hylek EM,
Alexander JH.
et al.
Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. Eur Heart J 2015; 36 (20) 1264-1272
33
Schulman S,
Gross PL,
Ritchie B.
et al;
Study Investigators.
Prothrombin complex concentrate for major bleeding on factor Xa inhibitors: a prospective cohort study. Thromb Haemost 2018; 118 (05) 842-851
34
Majeed A,
Ågren A,
Holmström M.
et al.
Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study. Blood 2017; 130 (15) 1706-1712
35
Gómez-Outes A,
Alcubilla P,
Calvo-Rojas G.
et al.
Meta-analysis of reversal agents for severe bleeding associated with direct oral anticoagulants. J Am Coll Cardiol 2021; 77 (24) 2987-3001
36
Witt DM,
Nieuwlaat R,
Clark NP.
et al.
American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv 2018; 2 (22) 3257-3291
37
Levy JH,
Shaw JR,
Castellucci LA.
et al.
Reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost 2024; 22 (10) 2889-2899
38
Tomaselli GF,
Mahaffey KW,
Cuker A.
et al.
2020 ACC Expert Consensus Decision Pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2020; 76 (05) 594-622
39 National Advisory Committee on Blood and Blood Products. Recommendations for Use of Prothrombin Complex Concentrates in Canada. Published 2022. Accessed July 16, 2024 at:
https://nacblood.ca/en/resource/recommendations-use-prothrombin-complex-concentrates-canada
40
Kaatz S,
Ahmad D,
Spyropoulos AC,
Schulman S.
Subcommittee on Control of Anticoagulation.
Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 2015; 13 (11) 2119-2126
41
McGee S,
Abernethy III WB,
Simel DL.
The rational clinical examination. Is this patient hypovolemic?. JAMA 1999; 281 (11) 1022-1029
42
Chornenki NLJ,
Um KJ,
Mendoza PA.
et al.
Risk of venous and arterial thrombosis in non-surgical patients receiving systemic tranexamic acid: a systematic review and meta-analysis. Thromb Res 2019; 179: 81-86
43
Collaborators H-IT.
HALT-IT Trial Collaborators.
Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial. Lancet 2020; 395 (10241): 1927-1936
44
Shakur H,
Roberts I,
Bautista R.
et al;
CRASH-2 Trial Collaborators.
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010; 376 (9734) 23-32
45
CRASH-3 trial collaborators.
Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. Lancet 2019; 394 (10210): 1713-1723
46
Sprigg N,
Flaherty K,
Appleton JP.
et al;
TICH-2 Investigators.
Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial. Lancet 2018; 391 (10135): 2107-2115
47
Polymeris AA,
Karwacki GM,
Siepen BM.
et al;
TICH-NOAC Investigators.
Tranexamic acid for intracerebral hemorrhage in patients on non-vitamin K antagonist oral anticoagulants (TICH-NOAC): a multicenter, randomized, placebo-controlled, phase 2 trial. Stroke 2023; 54 (09) 2223-2234
48
Roberts HR,
Monroe DM,
White GC.
The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 2004; 104 (13) 3858-3864
49
Telgt DS,
Macik BG,
McCord DM,
Monroe DM,
Roberts HR.
Mechanism by which recombinant factor VIIa shortens the aPTT: activation of factor X in the absence of tissue factor. Thromb Res 1989; 56 (05) 603-609
50
O'Connell KA,
Wood JJ,
Wise RP,
Lozier JN,
Braun MM.
Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006; 295 (03) 293-298
51 Pfizer. Eliquis Product Monograph. Published 2015 . Accessed October 12, 2015 at: https://www.bms.com/assets/bms/ca/documents/productmonograph/ELIQUIS_EN_PM.pdf
52 Bayer PHarma AG. Xarelto Product Monograph. Published 2015 . Accessed October 12, 2015 at: https://www.bayer.com/sites/default/files/2020-11/xarelto-pm-en.pdf
53 Servier Canada Inc. Lixiana Product Monograph. Published 2024 . Accessed July 16, 2024 at:
https://servier.ca/wp-content/uploads/sites/24/2022/11/Product-monograph-LIXIANA.pdf?time=1704916575
54
Cuker A,
Siegal DM,
Crowther MA,
Garcia DA.
Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol 2014; 64 (11) 1128-1139
55
Samuelson BT,
Cuker A,
Siegal DM,
Crowther M,
Garcia DA.
Laboratory assessment of the anticoagulant activity of direct oral anticoagulants: a systematic review. Chest 2017; 151 (01) 127-138
56
Mithoowani S,
Moffat KA,
Gupta A,
Carlino SA,
Crowther MA.
Low molecular weight heparin anti-Xa assays can identify patients with clinically important apixaban and rivaroxaban drug levels. Thromb Res 2022; 215: 1-4
57
Rimsans J,
Douxfils J,
Smythe MA.
et al.
Overview and practical application of coagulation assays in managing anticoagulation with direct oral anticoagulants (DOACs). Curr Pharmacol Rep 2020; 6: 241-259
58
Dentali F,
Marchesi C,
Giorgi Pierfranceschi M.
et al.
Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thromb Haemost 2011; 106 (03) 429-438
59
Pandey S,
Vyas GN.
Adverse effects of plasma transfusion. Transfusion 2012; 52 (Suppl 1): 65S-79S
60 Bloody Easy 5.1: Blood Transfusions, Blood Alternatives and Transfusion Reactions. A Guide to Transfusion Medicine, fifth Edition Handbook. Published 2023. Accessed July 16, 2024 at:
https://transfusionontario.org/en/bloody-easy-5-blood-transfusions-blood-alternatives-and-transfusion-reactions-a-guide-to-transfusion-medicine-fifth-edition-handbook/
61
Sarode R,
Milling Jr TJ,
Refaai MA.
et al.
Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation 2013; 128 (11) 1234-1243
62
Witt DM,
Nieuwlaat R,
Clark NP.
et al.
American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv 2018; 2 (22) 3257-3291
63
Ageno W,
Gallus AS,
Wittkowsky A,
Crowther M,
Hylek EM,
Palareti G.
Oral Anticoagulant Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (02) e44S-e88S
64 Product Monograph: Octaplex. Published 2017. Accessed July 16, 2024 at:
https://pdf.hres.ca/dpd_pm/00041970.PDF
65 KCentra Prescribing Information. Published 2023. Accessed July 16, 2024 at:
https://labeling.cslbehring.com/PI/US/Kcentra/EN/Kcentra-Prescribing-Information.pdf
66
Schiele F,
van Ryn J,
Canada K.
et al.
A specific antidote for dabigatran: functional and structural characterization. Blood 2013; 121 (18) 3554-3562
67
Eikelboom JW,
Quinlan DJ,
van Ryn J,
Weitz JI.
Idarucizumab. Circulation 2015; 132 (25) 2412-2422
68
Pollack Jr CV,
Reilly PA,
Eikelboom J.
et al.
Idarucizumab for dabigatran reversal. N Engl J Med 2015; 373 (06) 511-520
69
Shaw JR,
Siegal DM.
Pharmacological reversal of the direct oral anticoagulants—a comprehensive review of the literature. Res Pract Thromb Haemost 2018; 2 (02) 251-265
70
Kim B,
Garcia DA.
What is the role of hemodialysis for dabigatran-associated major bleeding?. Hematology (Am Soc Hematol Educ Program) 2014; 2014 (01) 514-517
71
Lu G,
DeGuzman FR,
Hollenbach SJ.
et al.
A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013; 19 (04) 446-451
72
Siegal DM,
Curnutte JT,
Connolly SJ.
et al.
Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 2015; 373 (25) 2413-2424
73
Milling Jr TJ,
Middeldorp S,
Xu L.
et al;
ANNEXA-4 Investigators.
Final study report of andexanet alfa for major bleeding with factor Xa inhibitors. Circulation 2023; 147 (13) 1026-1038
74
Connolly SJ,
Sharma M,
Cohen AT.
et al;
ANNEXA-I Investigators.
Andexanet for factor Xa inhibitor-associated acute intracerebral hemorrhage. N Engl J Med 2024; 390 (19) 1745-1755
75
Shoamanesh A,
Demchuk A,
Seiffge D.
et al.
Predictors of Hematoma Expansion and Response to Andexanet in ANNEXA-I. Presented at: 2024 International Stroke Conference;. February 7–9, 2024; Phoenix, AZ
76
Davis SM,
Broderick J,
Hennerici M.
et al;
Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators.
Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology 2006; 66 (08) 1175-1181
77
Dowlatshahi D,
Demchuk AM,
Flaherty ML,
Ali M,
Lyden PL,
Smith EE.
VISTA Collaboration.
Defining hematoma expansion in intracerebral hemorrhage: relationship with patient outcomes. Neurology 2011; 76 (14) 1238-1244
78
Morotti A,
Boulouis G,
Dowlatshahi D.
et al.
Intracerebral haemorrhage expansion: definitions, predictors, and prevention. Lancet Neurol 2023; 22 (02) 159-171
79
Seiffge D,
Sandset EC,
Shoamanesh A.
et al.
Consequences of Haematoma Expansion and Thromboembolic Events in Patients with Factor Xa Inhibitor–Associated ICH in ANNEXA-I. Presented at European Organization on Stroke Conference; May 15, 2024 ; Basel, Switzerland
80
Dobesh PP,
Fermann GJ,
Christoph MJ.
et al.
Lower mortality with andexanet alfa vs 4-factor prothrombin complex concentrate for factor Xa inhibitor-related major bleeding in a U.S. hospital-based observational study. Res Pract Thromb Haemost 2023; 7 (06) 102192
81
Cohen AT,
Lewis M,
Connor A.
et al.
Thirty-day mortality with andexanet alfa compared with prothrombin complex concentrate therapy for life-threatening direct oral anticoagulant-related bleeding. J Am Coll Emerg Physicians Open 2022; 3 (02) e12655
82
Zahir H,
Brown KS,
Vandell AG.
et al.
Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. Circulation 2015; 131 (01) 82-90
83
Lu G,
Lin J,
Bui K,
Curnutte JT,
Conley PB.
Andexanet versus prothrombin complex concentrates: differences in reversal of factor Xa inhibitors in in vitro thrombin generation. Res Pract Thromb Haemost 2020; 4 (08) 1282-1294
84
Chiasakul T,
Crowther M,
Cuker A.
Four-factor prothrombin complex concentrate for the treatment of oral factor Xa inhibitor-associated bleeding: a meta-analysis of fixed versus variable dosing. Res Pract Thromb Haemost 2023; 7 (02) 100107
85
Ip B,
Pan S,
Yuan Z.
et al.
Prothrombin complex concentrate vs conservative management in ICH associated with direct oral anticoagulants. JAMA Netw Open 2024; 7 (02) e2354916
86
Milling Jr TJ,
King B,
Yue P.
et al;
ANNEXA-4 Investigators.
Restart of anticoagulant therapy and risk of thrombosis, rebleeding, and death after factor Xa inhibitor reversal in major bleeding patients. Thromb Haemost 2021; 121 (08) 1097-1106
87
Little DHW,
Sutradhar R,
Cerasuolo JO.
et al.
Rates of rebleeding, thrombosis and mortality associated with resumption of anticoagulant therapy after anticoagulant-related bleeding. CMAJ 2021; 193 (09) E304-E309
88
Witt DM,
Delate T,
Garcia DA.
et al.
Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding. Arch Intern Med 2012; 172 (19) 1484-1491
89
Little D,
Chai-Adisaksopha C,
Hillis C.
et al.
Resumption of anticoagulant therapy after anticoagulant-related gastrointestinal bleeding: a systematic review and meta-analysis. Thromb Res 2019; 175: 102-109
90
Qureshi W,
Mittal C,
Patsias I.
et al.
Restarting anticoagulation and outcomes after major gastrointestinal bleeding in atrial fibrillation. Am J Cardiol 2014; 113 (04) 662-668
91
Murthy SB,
Gupta A,
Merkler AE.
et al.
Restarting anticoagulant therapy after intracranial hemorrhage: a systematic review and meta-analysis. Stroke 2017; 48 (06) 1594-1600
92
Candeloro M,
van Es N,
Cantor N.
et al.
Recurrent bleeding and thrombotic events after resumption of oral anticoagulants following gastrointestinal bleeding: communication from the ISTH SSC Subcommittee on Control of Anticoagulation. J Thromb Haemost 2021; 19 (10) 2618-2628
93
Little DHW,
Robertson T,
Douketis J.
et al.
Management of antithrombotic therapy after gastrointestinal bleeding: a mixed methods study of health-care providers. J Thromb Haemost 2021; 19 (01) 153-160
94
Hart RG,
Diener HC,
Yang S.
et al.
Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke 2012; 43 (06) 1511-1517
95
Nielsen PB,
Larsen TB,
Skjøth F,
Lip GY.
Outcomes associated with resuming warfarin treatment after hemorrhagic stroke or traumatic intracranial hemorrhage in patients with atrial fibrillation. JAMA Intern Med 2017; 177 (04) 563-570
96
Kuramatsu JB,
Gerner ST,
Schellinger PD.
et al.
Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA 2015; 313 (08) 824-836
97
So SC.
SoSTART Collaboration.
Effects of oral anticoagulation for atrial fibrillation after spontaneous intracranial haemorrhage in the UK: a randomised, open-label, assessor-masked, pilot-phase, non-inferiority trial. Lancet Neurol 2021; 20 (10) 842-853
98
Ottosen TP,
Grijota M,
Hansen ML.
et al.
Use of antithrombotic therapy and long-term clinical outcome among patients surviving intracerebral hemorrhage. Stroke 2016; 47 (07) 1837-1843
99
Nielsen PB,
Larsen TB,
Skjøth F,
Gorst-Rasmussen A,
Rasmussen LH,
Lip GY.
Restarting anticoagulant treatment after intracranial hemorrhage in patients with atrial fibrillation and the impact on recurrent stroke, mortality, and bleeding: a nationwide cohort study. Circulation 2015; 132 (06) 517-525
100
Nielsen PB,
Skjøth F,
Søgaard M,
Kjældgaard JN,
Lip GYH,
Larsen TB.
Non-vitamin K antagonist oral anticoagulants versus warfarin in atrial fibrillation patients with intracerebral hemorrhage. Stroke 2019; 50 (04) 939-946
101
Schreuder FHBM,
van Nieuwenhuizen KM,
Hofmeijer J.
et al;
APACHE-AF Trial Investigators.
Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 trial. Lancet Neurol 2021; 20 (11) 907-916
102
Shoamanesh A.
ENRICH-AF Steering Committee.
Anticoagulation in patients with cerebral amyloid angiopathy. Lancet 2023; 402 (10411): 1418-1419
103
Pennlert J,
Overholser R,
Asplund K.
et al.
Optimal timing of anticoagulant treatment after intracerebral hemorrhage in patients with atrial fibrillation. Stroke 2017; 48 (02) 314-320
104
Majeed A,
Kim YK,
Roberts RS,
Holmström M,
Schulman S.
Optimal timing of resumption of warfarin after intracranial hemorrhage. Stroke 2010; 41 (12) 2860-2866
105
Huang XY,
Zhang JY,
Yu CY.
Whether it is safe to start anticoagulation after intracranial hemorrhage within 2 weeks: a systematic review and meta-analysis. Ibrain 2022; 8 (03) 377-388
106
Barra ME,
Forman R,
Long-Fazio B.
et al.
Optimal timing for resumption of anticoagulation after intracranial hemorrhage in patients with mechanical heart valves. J Am Heart Assoc 2024; 13 (10) e032094
107
Xu Y,
Shoamanesh A,
Schulman S.
et al.
Oral anticoagulant re-initiation following intracerebral hemorrhage in non-valvular atrial fibrillation: global survey of the practices of neurologists, neurosurgeons and thrombosis experts. PLoS One 2018; 13 (01) e0191137
108
Greenberg SM,
Ziai WC,
Cordonnier C.
et al;
American Heart Association/American Stroke Association.
2022 guideline for the management of patients with spontaneous intracerebral hemorrhage: a guideline from the American Heart Association/American Stroke Association. Stroke 2022; 53 (07) e282-e361
109
Burnett A,
Rudd KM,
Triller D.
Advancing anticoagulation stewardship: a call to action for stewardship from the US-based anticoagulation forum. Thromb Update 2022; 9: 100125
110
Chadha A,
Guirguis M,
Bungard TJ.
DOAC drug interactions management resource. Can Pharm J 2022; 155 (06) 315-325
111
Olsen AS,
McGettigan P,
Gerds TA.
et al.
Risk of gastrointestinal bleeding associated with oral anticoagulation and non-steroidal anti-inflammatory drugs in patients with atrial fibrillation: a nationwide study. Eur Heart J Cardiovasc Pharmacother 2020; 6 (05) 292-300
112
Schaefer JK,
Errickson J,
Kong X.
et al.
Outcomes of direct oral anticoagulants with aspirin vs warfarin with aspirin: a registry-based cohort study. Res Pract Thromb Haemost 2024; 8 (04) 102449
113
Schaefer JK,
Errickson J,
Li Y.
et al.
Adverse events associated with the addition of aspirin to direct oral anticoagulant therapy without a clear indication. JAMA Intern Med 2021; 181 (06) 817-824
114
Tarn DM,
Barrientos M,
Wang AY,
Ramaprasad A,
Fang MC,
Schwartz JB.
Prevalence and knowledge of potential interactions between over-the-counter products and apixaban. J Am Geriatr Soc 2020; 68 (01) 155-162
115
Abebe W.
Review of herbal medications with the potential to cause bleeding: dental implications, and risk prediction and prevention avenues. EPMA J 2019; 10 (01) 51-64
116
Abraham NS,
Barkun AN,
Sauer BG.
et al.
American College of Gastroenterology-Canadian Association of Gastroenterology clinical practice guideline: management of anticoagulants and antiplatelets during acute gastrointestinal bleeding and the periendoscopic period. J Can Assoc Gastroenterol 2022; 5 (02) 100-101
117
Kent AP,
Brueckmann M,
Fraessdorf M.
et al.
Concomitant oral anticoagulant and nonsteroidal anti-inflammatory drug therapy in patients with atrial fibrillation. J Am Coll Cardiol 2018; 72 (03) 255-267
118 Boehringer Ingelheim Canada Ltd. Pradaxa Product Monograph. Published 2011 . Accessed October 12, 2015 at: http://www.boehringer-ingelheim.ca/content/dam/internet/opu/ca_EN/documents/humanhealth/product_monograph/PradaxaPMEN.pdf
119 Boerhinger Ingelheim Canada Ltd. Praxbind Product Monograph. Published 2019 . Accessed July 10, 2024 at:
https://www.boehringer-ingelheim.com/ca/bipdf/praxbind-product-monograph
120 Astra Zeneca Canada Inc. Ondexxya Product Monograph. Published 2023 . Accessed July 10, 2024 at: https://www.astrazeneca.ca/content/dam/az-ca/downloads/productinformation/ondexxya-product-monograph-en.pdf
留言 (0)